Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Nature medicine - 1 Sept 2017

Janouskova Hana, El Tekle Geniver, Bellini Elisa, Udeshi Namrata D, Rinaldi Anna, Ulbricht Anna, Bernasocchi Tiziano, Civenni Gianluca, Losa Marco, Svinkina Tanya, Bielski Craig M, Kryukov Gregory V, Cascione Luciano, Napoli Sara, Enchev Radoslav I, Mutch David G, Carney Michael E, Berchuck Andrew, Winterhoff Boris J N, Broaddus Russell R, Schraml Peter, Moch Holger, Bertoni Francesco, Catapano Carlo V, Peter Matthias, Carr Steven A, Garraway Levi A, Wild Peter J, Theurillat Jean-Philippe P

Abstract excerpt

It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azepines

Share to Carcinoma, Endometrioid

Share to Carcinosarcoma

Share to Cullin Proteins

Share to Heterocyclic Compounds, 3-Ring

Share to Neoplasms, Cystic, Mucinous, and Serous

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 28805821
DOI: 10.1038/nm.4372
PMCID: PMC5592092

Genes

SPOP
BRD2
BRD3
BRD4
CUL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.PMID 28805821Read ↗

Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.Semantic proximity Read ↗

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.Semantic proximity Read ↗

SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic ImplicationsSemantic proximity Read ↗

SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.Semantic proximity Read ↗

Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.Semantic proximity Read ↗

Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.Semantic proximity Read ↗

Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.Semantic proximity Read ↗

Deregulation of SPOP in Cancer.Semantic proximity Read ↗

G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer.Semantic proximity Read ↗

Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.Semantic proximity Read ↗

SPOP Gene Mutations in Prostate Cancer: Deciphering Their Role in Disease Characterization and Targeted Interventions on AR SignalingSemantic proximity Read ↗

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.